Invesco
URGN icon

Invesco’s UroGen Pharma URGN Stock Holding History

Invesco’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$954K Sell
25,927
-2,153
-8% -$58.3K ﹤0.01% 2942
2026
Q1 		$505K Buy
28,080
+1,014
+4% +$20.3K ﹤0.01% 3159
2025
Q4 		$634K Buy
27,066
+4,711
+21% +$102K ﹤0.01% 3114
2025
Q3 		$446K Buy
22,355
+9,614
+75% +$173K ﹤0.01% 3274
2025
Q2 		$175K Buy
12,741
+31
+0.2% +$297 ﹤0.01% 3549
2025
Q1 		$141K Sell
12,710
-746
-6% -$7.95K ﹤0.01% 3585
2024
Q4 		$143K Buy
13,456
+634
+5% +$7.59K ﹤0.01% 3575
2024
Q3 		$163K Buy
12,822
+1,159
+10% +$17.2K ﹤0.01% 3552
2024
Q2 		$196K Buy
11,663
+905
+8% +$12.9K ﹤0.01% 3627
2024
Q1 		$161K Buy
10,758
+656
+6% +$10.7K ﹤0.01% 3687
2023
Q4 		$152K Buy
10,102
+47
+0.5% +$610 ﹤0.01% 3615
2023
Q3 		$141K Buy
+10,055
New +$161K ﹤0.01% 3673
2019
Q1 		– Sell
-6,078
Closed -$262K – 3821
2018
Q4 		$262K Buy
+6,078
New +$273K ﹤0.01% 3491

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Invesco's URGN Position: Q2 2026 in Review

Invesco reduced its UroGen Pharma (URGN) stake by 7.7% in Q2 2026, selling an estimated $58.3K and leaving 25,927 shares worth $954K. The position accounts for ﹤0.01% of the portfolio, ranked #2942.

Invesco first reported a position in URGN in Q4 2018 and has held it in 13 quarters since. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Invesco held 25,927 shares of UroGen Pharma worth $954K as of Q2 2026.
  • Invesco sold 2,153 UroGen Pharma shares in Q2 2026, an estimated $58.3K.
  • UroGen Pharma made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2942 holding.
  • Invesco first reported a position in UroGen Pharma in Q4 2018 and has held it in 13 quarters since.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.